Coeptis Therapeutics, Inc. (COEP)
NASDAQ: COEP · IEX Real-Time Price · USD
0.260
-0.008 (-2.80%)
At close: Jul 26, 2024, 3:58 PM
0.263
+0.003 (0.96%)
After-hours: Jul 26, 2024, 6:28 PM EDT
Coeptis Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
9.65M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
XWELL | 31.77M |
PAVmed | 3.02M |
Senti Biosciences | 1.28M |
Mangoceuticals | 844.87K |
Traws Pharma | 226.00K |
Kazia Therapeutics | 15.65K |
COEP News
- 5 weeks ago - Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PRNewsWire
- 2 months ago - Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - PRNewsWire
- 2 months ago - Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - PRNewsWire
- 3 months ago - Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting - PRNewsWire
- 4 months ago - Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award - PRNewsWire
- 5 months ago - Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK - PRNewsWire
- 6 months ago - Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections - PRNewsWire
- 7 months ago - Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 - PRNewsWire